
The study highlights the crucial role of RAF1, a RAS effector, in the proliferation of both MSI and MSS colorectal cancer (CRC) cells, regardless of KRAS mutation status. A RAF1 transcriptomic signature associated with STAT3 activation was identified, and RAF1 ablation decreased STAT3 phosphorylation in CRC cells. These findings suggest that RAF1 could be a promising therapeutic target for CRC, supporting the development of selective RAF1 degraders for combination therapies in clinical settings.
Like
Save
Share